Social media

Over the past five years, ICON has participated in 840+ oncology and haematologic malignancy clinical studies globally. Meet ICON experts at #ESMO25, booth #3034 to learn how our flexible and fully customisable solutions...

ICON has done it again! For the third consecutive year, we’ve been named one of TIME and Statista’s World’s Best Companies of 2025. This honour celebrates our people, our purpose, and our progress. Thank you to everyone ...

Discover how our strong relationship with the sponsor, our proven track record of partnering with small #biotech firms, and our clear understanding that biotech companies require a different approach from larger pharmace...

ICON is excited to be part of #CoNSPIC 2025, organized by #IASCT. We look forward to seeing you there! https://ow.ly/2NGa50WVzt2

Are your obesity trials designed to meet today’s expectations? Discover how to integrate COAs + DHTs effectively in our live session. Reserve your spot: https://ow.ly/N0cu50WLeNl #ClinicalTrials #ObesityResearch #Digi...

Join ICON at the Biomarkers & Precision Medicine UK conference this 30 September - 1 October at the QEII Center, London. By visiting our team of experts at booth #51 you will learn how our biomarker, clinical, and consul...

We’re pleased to share that ICON will be joining #SCDMUS as a proud sponsor. From 27–30 September, the Baltimore Convention Center will host the leading global event for clinical data management, bringing together innova...

ICON’s Accelerated Pharmaceutical Solutions provide a seamless, end-to-end approach to formulation development for small molecules and biologics. Our comprehensive services cover everything from formulation screening a...

In just a few days, ICON will be at #DPHARM2025, 16–17 September at the Loews Philadelphia Hotel. Stop by booth #305 to learn how ICON’s comprehensive expertise in clinical development, consulting, and commercialization ...

Biomarkers aren’t just supporting drug development, they’re driving it. This expert-led report produced in conjunction with Drug Target Review explores how biomarker science is advancing trial design, accelerating clinic...

Latest issue out now. If you, like our thousands of subscribers, would like a convenient way to keep on top of the latest regulatory authority updates, sign up to our free newsletter today. Compiled and collated by ICON...

ICON invites you to connect with our biomarker experts Sean Downing and Jin Li at WorldCDx. We work across all major platforms including next generation sequencing, ddPCR, flow cytometry, histopathology and immunohistoch...